Alnylam, Cubist Say 90-Day Data Shows RSV Drug to Be Safe, Suggests Efficacy
July 23, 2009
Alnylam, Cubist Say 90-Day Data Shows RSV Drug to Be Safe, Suggests Efficacy
The companies said that they plan to evaluate these and other data, including ones related to second-generation RSV agents, "to determine the optimal development strategy and specific plans for all RSV indications."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam RSV Drug Fails in Phase IIb; Company to Weigh Options with Regulators
May 31, 2012 / Gene Silencing News - Unveiling New Strategy, Alnylam Aims to Debut Five Clinical Candidates by 2015
January 6, 2011 / Gene Silencing News - Alnylam May Not Reach Partnership Goal for ‘09, Partner Cubist to Focus on Follow-On RSV Rx
November 12, 2009 / Gene Silencing News - Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News